Pluristem Therapeutics’ (PSTI) “Buy” Rating Reaffirmed at Maxim Group

Share on StockTwits

Pluristem Therapeutics (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a research note issued to investors on Wednesday, AnalystRatings.com reports. They presently have a $8.00 target price on the biotechnology company’s stock. Maxim Group’s price target points to a potential upside of 111.64% from the company’s previous close.

Several other equities analysts have also recently commented on PSTI. Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $15.50 price target on shares of Pluristem Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $9.25.

PSTI stock traded down $0.02 during mid-day trading on Wednesday, hitting $3.78. 1,804 shares of the company were exchanged, compared to its average volume of 57,792. The firm has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $2.71. Pluristem Therapeutics has a twelve month low of $3.11 and a twelve month high of $11.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.74 and a quick ratio of 2.74.

Hedge funds and other institutional investors have recently modified their holdings of the company. United Capital Financial Advisers LLC raised its holdings in Pluristem Therapeutics by 37.8% during the second quarter. United Capital Financial Advisers LLC now owns 85,733 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 23,533 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Pluristem Therapeutics by 28.1% during the 2nd quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 33,630 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Pluristem Therapeutics in the 2nd quarter worth $231,000. Nikko Asset Management Americas Inc. grew its holdings in shares of Pluristem Therapeutics by 102.8% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after acquiring an additional 954,161 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Pluristem Therapeutics by 107.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after purchasing an additional 974,306 shares during the period. Institutional investors and hedge funds own 9.56% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Article: Market Timing – The Benefits and the Danger

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate EnLink Midstream LLC  to Post $0.06 EPS
Brokerages Anticipate EnLink Midstream LLC to Post $0.06 EPS
Akroma 24 Hour Trading Volume Reaches $6.00
Akroma 24 Hour Trading Volume Reaches $6.00
Pluristem Therapeutics’  “Buy” Rating Reaffirmed at Maxim Group
Pluristem Therapeutics’ “Buy” Rating Reaffirmed at Maxim Group
Ampleforth  24 Hour Trading Volume Hits $1.19 Million
Ampleforth 24 Hour Trading Volume Hits $1.19 Million
Vertcoin Achieves Market Capitalization of $12.84 Million
Vertcoin Achieves Market Capitalization of $12.84 Million
PFSweb, Inc.  Receives $4.58 Average Price Target from Analysts
PFSweb, Inc. Receives $4.58 Average Price Target from Analysts


© 2006-2019 Ticker Report